SERUM, URINE AND PERITONEAL-FLUID LEVELS OF 5-FU FOLLOWING INTRAPERITONEAL ADMINISTRATION
- 1 July 1987
- journal article
- research article
- Vol. 7 (4) , 829-832
Abstract
Seven patients with advanced colon cancer, refractory to conventional chemotherapy, and malignant disease confined to the intra-abdominal space received a total of 24 consecutive courses of ip 5-Fluorouracil (5-FU). 5-FU 1000 mg was administered in 2 L of warm (37.degree. C) dialysate daily for five consectuve days every 28 days. 5-FU concentrations in serum, peritoneal fluid and urine were measured by high pressure liquid chromatography (HPLC). The mean disappearance half-life of 5-FU from the peritoneal fluid was 1.6 hours with a mean permeability area product (PA) of 22.4 ml/min. The mean peritoneal AUC was 450 .+-. 165 times greater than the mean serum AUC. Ip 5-FU treatment is well tolerated, can be safely administered on an outpatients basis and produces a significant pharmacological advantages over conventional routes of administration.This publication has 5 references indexed in Scilit:
- Analysis of 5′-Deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- IP CISPLATIN IN PATIENTS WITH MALIGNANT ASCITES - PHARMACOKINETIC EVALUATION AND COMPARISON WITH THE IV ROUTE1983
- PHASE-I AND PHARMACOLOGICAL STUDIES OF 5-FLUOROURACIL ADMINISTERED INTRAPERITONEALLY1980
- PHARMACOKINETICS OF FLUOROURACIL IN HUMANS1978
- PHARMACOKINETIC RATIONALE FOR PERITONEAL DRUG ADMINISTRATION IN TREATMENT OF OVARIAN CANCER1978